September 3, 2020 08:19 AM EDTUpdated 10:43 AM

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Akebia $AKBA slammed directly into an unexpected brick wall Thursday morning, as the biotech reported a critical failure in its second Phase III study of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

Editor & Founder

Editor

Sign up to read this article for free.

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage